Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 43 articles: HTML format

Single Articles

April 2024
1. HU Y, Zhang M, Yang T, Mo Z, et al
   Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
   N Engl J Med. 2024;390:1467-1480.
   PubMed     Abstract available
   
   
   March 2024
2. VIPLER B
   "What's Lymphoma?" - Risks Posed by Immediate Release of Test Results to Patients.
   N Engl J Med. 2024;390:1064-1066.
   PubMed    
   
   
   December 2023
3. CHENG JW, Li JH
   Intravascular Large B-Cell Lymphoma.
   N Engl J Med. 2023;389:2188.
   PubMed    
   
   
   September 2023
4. WESTIN JR, To C, Locke FL
   Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply.
   N Engl J Med. 2023;389:1152-1153.
   PubMed    
   
   
   
5. ZHAO WL, Wu DP, Hu Y
   Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
   N Engl J Med. 2023;389:1152-1153.
   PubMed    
   
   
   July 2023
6. HOFACKER SA, Schmidt EP
   Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia. Reply.
   N Engl J Med. 2023;389:95.
   PubMed    
   
   
   
7. GUPTA A
   Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia.
   N Engl J Med. 2023;389:94-95.
   PubMed    
   
   
   June 2023
8. WESTIN JR, Oluwole OO, Kersten MJ, Miklos DB, et al
   Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
   N Engl J Med. 2023 Jun 5. doi: 10.1056/NEJMoa2301665.
   PubMed     Abstract available
   
   
   May 2023
9. BROWN JR, Cohen A, Shadman M
   Zanubrutinib in Chronic Lymphocytic Leukemia. Reply.
   N Engl J Med. 2023;388:1720-1721.
   PubMed    
   
   
   
10. LIANG Y, Gale RP
    Zanubrutinib in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;388:1720.
    PubMed    
    
    
    
11. BYRD JC, Rothbaum W
    Zanubrutinib in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;388:1719-1720.
    PubMed    
    
    
    April 2023
12. SCHMIDT EP, Shepard JO, Liu L
    Case 11-2023: A 67-Year-Old Man with Mantle-Cell Lymphoma and Hypoxemia.
    N Engl J Med. 2023;388:1416-1423.
    PubMed    
    
    
    December 2022
13. DICKINSON MJ, Carlo-Stella C, Morschhauser F, Bachy E, et al
    Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2022;387:2220-2231.
    PubMed     Abstract available
    
    
    
14. BARTLETT NL
    Bispecific Antibodies in Lymphoma - Another Win for T Cells.
    N Engl J Med. 2022;387:2285-2286.
    PubMed    
    
    
    November 2022
15. ROSCHEWSKI M, Bollard CM
    Are We Too Reliant on Radiation Therapy for Children with Hodgkin's Lymphoma?
    N Engl J Med. 2022;387:1710-1712.
    PubMed    
    
    
    
16. CASTELLINO SM, Pei Q, Parsons SK, Hodgson D, et al
    Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
    N Engl J Med. 2022;387:1649-1660.
    PubMed     Abstract available
    
    
    October 2022
17. ANSELL SM, Radford J, Straus DJ
    Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply.
    N Engl J Med. 2022;387:1527-1528.
    PubMed    
    
    
    
18. HASLAM A, Prasad V
    Brentuximab Vedotin in Advanced Hodgkin's Lymphoma.
    N Engl J Med. 2022;387:1527.
    PubMed    
    
    
    September 2022
19. WANG ML, Le Gouill S, Dreyling M
    Treatment of Mantle-Cell Lymphoma. Reply.
    N Engl J Med. 2022;387:1148.
    PubMed    
    
    
    
20. ESKAZAN AE
    Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1147-1148.
    PubMed    
    
    
    
21. FERHANOGLU B, Birtas Atesoglu E, Ozbalak M
    Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1147.
    PubMed    
    
    
    
22. CLIFF ERS, Dickinson M
    Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1146-1147.
    PubMed    
    
    
    
23. ROSCHEWSKI M, Staudt LM, Wilson WH
    Burkitt's Lymphoma.
    N Engl J Med. 2022;387:1111-1122.
    PubMed    
    
    
    
24. ARMITAGE JO, Longo DL
    Mantle-Cell Lymphoma. Reply.
    N Engl J Med. 2022;387:1050.
    PubMed    
    
    
    
25. YAVORKOVSKY LL
    Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1049.
    PubMed    
    
    
    July 2022
26. ANSELL SM, Radford J, Connors JM, Dlugosz-Danecka M, et al
    Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2022 Jul 13. doi: 10.1056/NEJMoa2206125.
    PubMed     Abstract available
    
    
    
27. LONGO DL, Armitage JO
    A Better Treatment for Advanced-Stage Hodgkin's Lymphoma?
    N Engl J Med. 2022 Jul 13. doi: 10.1056/NEJMe2207639.
    PubMed    
    
    
    June 2022
28. ARMITAGE JO, Longo DL
    Mantle-Cell Lymphoma.
    N Engl J Med. 2022;386:2495-2506.
    PubMed    
    
    
    
29. WANG ML, Jurczak W, Jerkeman M, Trotman J, et al
    Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2201817.
    PubMed     Abstract available
    
    
    May 2022
30. BERTONI F, Rossi D, Zucca E
    Marginal-Zone Lymphomas. Reply.
    N Engl J Med. 2022;386:1962-1963.
    PubMed    
    
    
    
31. HENRY B, Buffet P, Bates I
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:1962.
    PubMed    
    
    
    
32. MATUCHANSKY C
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:1962.
    PubMed    
    
    
    March 2022
33. FORST DA, Restrepo JA, Gonzalez RG, Jones PS, et al
    Case 7-2022: A 65-Year-Old Woman with Depression, Recurrent Falls, and Inability to Care for Herself.
    N Engl J Med. 2022;386:977-986.
    PubMed    
    
    
    February 2022
34. ROSSI D, Bertoni F, Zucca E
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:568-581.
    PubMed    
    
    
    January 2022
35. SPANJAART AM, van der Valk FM, van Rooijen G, Brouwer MC, et al
    Confused about Confusion.
    N Engl J Med. 2022;386:80-87.
    PubMed    
    
    
    December 2021
36. TILLY H, Morschhauser F, Sehn LH, Friedberg JW, et al
    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2115304.
    PubMed     Abstract available
    
    
    
37. BISHOP MR, Dickinson M, Purtill D, Barba P, et al
    Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2116596.
    PubMed     Abstract available
    
    
    
38. ROSCHEWSKI M, Longo DL, Wilson WH
    CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMe2118899.
    PubMed    
    
    
    
39. LOCKE FL, Miklos DB, Jacobson CA, Perales MA, et al
    Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 11. doi: 10.1056/NEJMoa2116133.
    PubMed     Abstract available
    
    
    September 2021
40. STOKKE JL, Szymanski LJ, Bankamp B, Pratt F, et al
    MMR Vaccine-Associated Disseminated Measles in an Immunocompromised Adolescent.
    N Engl J Med. 2021;385:1246-1248.
    PubMed    
    
    
    
41. LYU X, Guan X
    Gingival Ulceration.
    N Engl J Med. 2021;385:e33.
    PubMed    
    
    
    June 2021
42. SEHN LH, Salles G
    Diffuse Large B-Cell Lymphoma. Reply.
    N Engl J Med. 2021;384:2262.
    PubMed    
    
    
    
43. LANG R, Gill MJ
    Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2021;384:2261-2262.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.